Cost-effectiveness analysis of prolanis of type 2 diabetes mellitus patients on three community health centers in Bandung, Indonesia

Abstract

Objective: The purpose of this study was to compare the cost-effectiveness of T2DM patients in community health centers (Pusat Kesehatan Masyarakat, Puskesmas) of Rancaekek, Linggar, and Nanjungmekar. Methods: The medicine was a combination of metformin and glimepiride; the outcome parameter was fasting glucose level, cost components were fee of BPJS class III and transportation cost with the patient's perspective. Pharmacoeconomic method was cost-effectiveness analysis. Respondents were given counseling about the importance of medicine consumption. Results: There were 60 respondents, which met the inclusion criteria, then grouped by gender (male (15%) and female (85%)) and age (the highest incidence was the range from 56 to 65 y old, 36.67%). The average cost-effectiveness ratio of Prolanis in the Puskesmas of Rancaekek, Linggar, and Nanjungmekar was 1,073, 956 and 1,885 IDR per decreased glucose level, respectively. The statistical analysis of decreased blood glucose was 0.341 and the Prolanis cost was 0.399, which no difference between decreased blood glucose and Prolanis costs in the three Puskesmas. Conclusions: The Prolanis of Linggar Puskesmas was the most cost-effective compared to the Rancaekek and Nanjungmekar Puskesmas.